This active molecular is a highly selective neutrophil elastase inhibitor .IC50 for HNE is 0.065 nM, LipE is 7.2. BAY 85-8501 was being tested in clinical studies for the treatment of pulmonary diseases. In Feb 2013, Phase-II clinical trials in Bronchiectasis in Spain were on going. In Mar 2013, Phase-II clinical trials in Bronchiectasis in France, Germany and Italy were on going. In Jun 2014, Bayer completed a phase IIa trial in Bronchiectasis in United Kingdom, Spain, France, Germany and Italy.